Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30781119 | 1.00 | SOS1 (0.37) | SOS1HTR6MAPTHTR1BHTR2A | |
| Hydrochloric Acid SCHEMBL30781456 | 0.99 | SOS1 (0.38) | SOS1HTR6 | |
| Hydrochloric Acid SCHEMBL27146499 | 0.99 | SOS1 (0.38) | SOS1HTR6 | |
| SCHEMBL27143073 | 0.80 | USP7 (0.37) | SOS1HTR6 | |
| SCHEMBL30781135 | 0.80 | USP7 (0.37) | SOS1HTR6 | |
| Hydrochloric Acid SCHEMBL30781408 | 0.80 | USP7 (0.37) | SOS1HTR6 | |
| Hydrochloric Acid SCHEMBL27147190 | 0.80 | USP7 (0.37) | SOS1HTR6 | |
| SCHEMBL30781299 | 0.79 | USP7 (0.44) | — | |
| SCHEMBL30781268 | 0.79 | USP7 (0.44) | — | |
| SCHEMBL30781283 | 0.79 | USP7 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | claimed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | claimed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | SOS1 2143/4885HTR6 3821/4885MAPT 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.